OTX015 clinical trials
Also written MK-8628, OTX015 and Birabresib.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses OTX015 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Merck Sharp & Dohme LLC (2)
Studies
Open first, then newest update. How each study uses OTX015 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)TerminatedPhase 1Merck Sharp & Dohme LLCNCT02698189Written as Birabresib Dose 20 mg
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)TerminatedPhase 1Merck Sharp & Dohme LLCNCT02698176Written as Birabresib
- A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)CompletedPhase 1Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01713582Written as OTX015/Birabresib
- A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)CompletedPhase 1Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02259114Written as Birabresib
- A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)TerminatedPhase 2Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02296476Written as Birabresib